Table 2. Cancer treatment before study entry and after vaccination.
|
Cohort |
||||
|---|---|---|---|---|
| Class of agent, n (%) | 1 | 2 | 3 | Total |
| Before study entry | ||||
| Chemotherapy | ||||
| Antimetabolitesa | 2 (66.7) | 0 (0.0) | 1 (33.3) | 3 (33.3) |
| Antimicrotubulesb | 1 (33.3) | 2 (66.7) | 2 (66.7) | 5 (55.6) |
| Target agentc | 2 (66.7) | 2 (66.7) | 1 (33.3) | 5 (55.6) |
| Chemotherapy combinationd | 3 (100) | 3 (100) | 3 (100) | 9 (100) |
| Hormone therapye | 2 (66.7) | 1 (33.3) | 1 (33.3) | 4 (44.4) |
| Supportive therapyf | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (33.3) |
| After vaccination | ||||
| Chemotherapy | ||||
| Cytotoxic antibioticsg | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
| Antimicrotubulesh | 1 (33.3) | 0 (0.0) | 1 (33.3) | 2 (22.2) |
| Chemotherapy combinationi | 2 (66.7) | 2 (66.7) | 1 (33.3) | 5 (55.6) |
| Hormone therapyj | 1 (33.3) | 1 (33.3) | 0 (0.0) | 2 (22.2) |
| Supportive therapyk | 2 (66.7) | 1 (33.3) | 1 (33.3) | 4 (44.4) |
Two subjects in cohort 1 (capecitabine) and one subject in cohort 3 (gemcitabine) had received antimetabolite chemotherapeutic agents before study entry.
One subject in cohort 1 (paclitaxel), two subjects in cohort 2 (paclitaxel), and two subjects in cohort 3 (docetaxel or paclitaxel) had received microtubule-targeted chemotherapeutic agent.
Two subjects in cohort 1, two subjects in cohort 2, and one subject in cohort 3 had received trastuzumab as HER2-targeted agent.
Nine subjects had been treated with combination regimens; 5-FU+cyclophosphamide+methotrexate, cyclophosphamide +doxorubicin, carboplatin+paclitaxel, capecitabine+vinorelbine, gemcitabine+vinorelbine, 5-FU+doxorubicin+cyclophosphamide, trastuzumab+paclitaxel, vinorelbine+gemcitabine, capecitabine+lapatinib, pazopanib+lapatinib, doxorubicin+docetaxel, gemcitabine+cisplatin.
Hormone therapy: tamoxifen, exemestane, and letrozole,
Supportive therapy: goserelin, zoledronic acid, and pamidronate.
One subject in cohort 1 (mitomycin and doxorubicin) had received cytotoxic antibiotics agents after vaccination.
One subject in cohort 1 (vinblastine) and one subject in cohort 3 (paclitaxel) had received microtubule-targeted chemotherapeutic agent.
Five subjects had been treated with combination regimens; 5-FU+cyclophosphamide+methotrexate, mitomycin+vinblastine, doxorubicin+cyclophosphamide, and gemcitabine+vinorelbine.
One subject in cohort 1 and 2 had received letrozole hormone therapy.
Supportive therapy: methylprednisolone, pamidronate, and zoledronic acid.